A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar” or the "Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

AstraZeneca is holding crisis talks with the Chinese authorities after the arrest of its boss in the country. The ...

AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore, which will create over 800 jobs.

AstraZeneca plans to hire over 800 in Singapore for engineering, quality, technical services, and supply chain roles at its ...

China is among the largest pharma markets globally—and a major market for AstraZeneca specifically. Last year, the pharma ...

Pharmaceutical giant AstraZeneca has confirmed that Leon Wang, the head of its China operations, had been detained.